BioSenic S.A. (EBR:BIOS)

Market Cap	1.44M
Revenue (ttm)	-2.39M
Net Income (ttm)	-4.00M
Shares Out	652.86M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,100
Average Volume	1,326,781
Open	0.0024
Previous Close	0.0022
Day's Range	0.0022 - 0.0024
52-Week Range	0.0012 - 0.0155
Beta	-2.43
RSI	43.92
Earnings Date	Oct 27, 2025

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company’s technologies include arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops ArsciCor, an oral medication in Phase III clinical trial and for the treatment for chronic graft-versus-host disease; JTA-004, an intra-articular injectable ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: François Rieger
• Employees: 7
• Stock Exchange: Euronext Brussels
• Ticker Symbol: BIOS

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.